Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Università del Piemonte Orientale Home
Italiano
English
Home
Profili
Unità di ricerca
Apparecchiatura
Progetti
Risultato della ricerca
Ricerca per competenza, nome o affiliazione
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Alberto Papi
, Michael G. Ison
, Joanne M. Langley
, Dong Gun Lee
, Isabel Leroux-Roels
, Federico Martinon-Torres
, Tino F. Schwarz
, Richard N. Van Zyl-Smit
, Laura Campora
, Nancy Dezutter
, Nathalie De Schrevel
, Laurence Fissette
, Marie Pierre David
, Marie Van Der Wielen
, Lusine Kostanyan
, Veronica Hulstrøm
Risultato della ricerca
:
Contributo su rivista
›
Articolo in rivista
›
peer review
Panoramica
Fingerprint
Fingerprint
Entra nei temi di ricerca di 'Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults'. Insieme formano una fingerprint unica.
Ordina per
Peso
Alfabetico
Keyphrases
Older Adults
100%
F Protein
100%
Protein Vaccine
100%
Respiratory Syncytial Virus
100%
Prefusion F
100%
Lower Respiratory Tract Infection
44%
Vaccine Effectiveness
27%
Acute Respiratory Infection
27%
Confidence Interval
22%
Placebo
16%
Quantitative PCR
11%
Virus Subtypes
11%
One Dose
11%
Coexisting Conditions
11%
Lower Limit
5%
Placebo Groups
5%
Moderate to Severe
5%
Placebo-controlled
5%
Age Groups
5%
Phase II Trial
5%
Adverse Events
5%
Serious Adverse Events
5%
Clinical Signs
5%
Safety Profile
5%
Protein-based
5%
Vaccine Antigen
5%
Clinical Complications
5%
Moderate Severity
5%
Acceptable Safety
5%
Mandatory Vaccines
5%
Potential Immune-mediated Diseases
5%
Clinical Death
5%
B Subtype
5%
Respiratory Syncytial Virus Infection
5%
Adjuvanted
5%
Medicine and Dentistry
Human Respiratory Syncytial Virus
100%
Respiratory Disease
47%
Lower Respiratory Tract
47%
Placebo
29%
Respiratory Tract Infection
29%
Vaccine Efficacy
29%
Adverse Event
11%
Single Drug Dose
11%
Reverse Transcription Polymerase Chain Reaction
11%
Diseases
5%
Human Respiratory Syncytial Virus A
5%
Respiratory Syncytial Virus Infection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Human Respiratory Syncytial Virus
100%
Respiratory Tract Disease
47%
Placebo
29%
Respiratory Tract Infection
29%
Vaccine Efficacy
29%
RNA Directed DNA Polymerase
11%
Adverse Event
11%
Diseases
5%
Respiratory Syncytial Virus Infection
5%
Human Respiratory Syncytial Virus A
5%
Immunology and Microbiology
Human Respiratory Syncytial Virus
100%
Lower Respiratory Tract
47%
Vaccine Efficacy
29%
Reverse Transcription Polymerase Chain Reaction
11%
Respiratory Syncytial Virus Infection
5%
Human Respiratory Syncytial Virus A
5%
Biochemistry, Genetics and Molecular Biology
Human Respiratory Syncytial Virus
100%
Single Drug Dose
11%
Reverse Transcription Polymerase Chain Reaction
11%
Human Respiratory Syncytial Virus A
5%